HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-05-2005, 04:20 AM   #1
Christine MH
Guest
 
Posts: n/a
At the San Antonio Breast Cancer Symposium, the updated results on two previously released phase I trials of its APC8024 breast cancer vaccine involving a total of thirty women with advanced breast cancer were announced. Over 90% of these women had progressed on herceptin and chemotherapy. During the trial, women received no other anti-cancer therapy.

The most important bits:

"The median time to disease progression was 10 weeks (range 2-75 weeks), and 3 patients remain free of evidence of disease progression at 36 weeks (ongoing), 77 weeks and 94 weeks (both at time of study completion)."

"APC8024 was well tolerated in all patients who participated in the study, with no reported treatment-related Grade 3 or 4 adverse events. The most commonly reported Grade 1 and 2 adverse events were infusion-related mild and transient fever, fatigue and rigors."

"Based on the encouraging data from these two Phase 1 studies, we are planning to initiate a Phase 2 trial with APC8024 in metastatic breast cancer in the coming year."

Personally, I found it encouraging that in three women (10 percent) the disease did not progress for at least sixteen months after they had received the therapy.Dendreon's APC8024 Immunotherapy Shows Promise in Advanced Breast Cancer
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:40 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter